Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasm, Residual × fludarabine × Clear all

Phase

Status

Sponsor Class

OTHER 12 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 33 Multiple Myeloma 26 Leukemia, Lymphocytic, Chronic, B-Cell 24 Lymphoma, Non-Hodgkin 22 Recurrence 21 Lymphoma 20 Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Lymphoma, Follicular 13 Lymphoma, B-Cell 13 Leukemia 13 Carcinoma, Non-Small-Cell Lung 13 Lymphoma, Mantle-Cell 12 Stomach Neoplasms 9 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Myelodysplastic Syndromes 6 Lymphoma, B-Cell, Marginal Zone 6 Carcinoma, Renal Cell 6 Uterine Cervical Neoplasms 5 Triple Negative Breast Neoplasms 5 Melanoma 5 Liposarcoma, Myxoid 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Neoplasm Metastasis 4 Myasthenia Gravis 4

Interventions

blinatumomab 5 midostaurin 2 Azacitidine 2 venetoclax 1 tisagenlecleucel 1 siremadlin 1 sabatolimab 1 pulrodemstat besilate 1 posaconazole 1 fludarabine phosphate 1 fludarabine 1 Zoledronic Acid 1 Vitamin D 1 N,N-dicyclohexyl-isoborneol-10-sulfonamide 1 Midazolam 1 Idarubicin 1 Drug Therapy 1 Daunorubicin 1 Cytarabine 1 Cyclophosphamide 1 Calcium 1 CD3 Complex 1 Anthracyclines 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06500273 2026-03-18

ALPHA3

Allogene Therapeutics

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡